Digital Citeline Awards 2020
The Citeline Awards (previously known as the CARE Awards) 2020
The 2020 Digital Citeline Awards took place September, 17. Congratulations to all the winners and thanks to all who entered, attended and sponsored. Click here to view the full list of winners.
The Citeline Awards, gather distinguished leaders in the biopharmaceutical, CRO, and diagnostic industries from all corners of the globe. Follow us - @Citeline_Awards #Citeline_Awards
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies.With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,100 employees.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostic companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.
Medidata, Medidata Rave, and Acorn AI are registered trademarks of Medidata Solutions, Inc., a wholly-owned subsidiary of Dassault Systèmes.
Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.